- Home
- PTON vs XENE Comparison
PTON vs XENE Comparison
Compare PTON & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTON
- XENE
- Stock Information
- Founded
- PTON 2012
- XENE 1996
- Country
- PTON United States
- XENE Canada
- Employees
- PTON N/A
- XENE N/A
- Industry
- PTON Recreational Games/Products/Toys
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- PTON Consumer Discretionary
- XENE Health Care
- Exchange
- PTON Nasdaq
- XENE Nasdaq
- Market Cap
- PTON 3.6B
- XENE 3.3B
- IPO Year
- PTON 2019
- XENE 2014
- Fundamental
- Price
- PTON $9.38
- XENE $38.63
- Analyst Decision
- PTON Hold
- XENE Strong Buy
- Analyst Count
- PTON 19
- XENE 9
- Target Price
- PTON $6.58
- XENE $56.67
- AVG Volume (30 Days)
- PTON 13.4M
- XENE 418.4K
- Earning Date
- PTON 01-30-2025
- XENE 11-12-2024
- Dividend Yield
- PTON N/A
- XENE N/A
- EPS Growth
- PTON N/A
- XENE N/A
- EPS
- PTON N/A
- XENE N/A
- Revenue
- PTON $2,690,700,000.00
- XENE N/A
- Revenue This Year
- PTON N/A
- XENE N/A
- Revenue Next Year
- PTON $1.35
- XENE $1,599.99
- P/E Ratio
- PTON N/A
- XENE N/A
- Revenue Growth
- PTON N/A
- XENE N/A
- 52 Week Low
- PTON $2.70
- XENE $35.53
- 52 Week High
- PTON $10.90
- XENE $50.99
- Technical
- Relative Strength Index (RSI)
- PTON 52.14
- XENE 39.23
- Support Level
- PTON $9.24
- XENE $37.52
- Resistance Level
- PTON $10.90
- XENE $41.62
- Average True Range (ATR)
- PTON 0.71
- XENE 1.66
- MACD
- PTON -0.16
- XENE -0.34
- Stochastic Oscillator
- PTON 22.51
- XENE 18.94
About PTON Peloton Interactive Inc.
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of bike and tread and related accessories sales, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue is generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from the International markets.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.